Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - European Journal of Cancer
Novartis AG (NVS) Updates on Kisqali® MONALEESA-3 ESMO Data - Slideshow (NYSE:NVS) | Seeking Alpha
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < 기사본문 - KBR
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
NEJM on Twitter: "In the MONALEESA-7 trial, ribociclib + endocrine therapy resulted in significantly longer progression-free survival than endocrine therapy alone. This article reports the results of a protocol-specified second interim analysis
BOOG Study Center - Studie
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial - Clinical Breast Cancer
YIR On Demand Breast Hope S Rugo, MD Professor of Medicine - ppt download
NEJM on Twitter: "In the MONALEESA-7 trial, ribociclib + endocrine therapy resulted in significantly longer progression-free survival than endocrine therapy alone. This article reports the results of a protocol-specified second interim analysis
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials - ESMO Open
MONALEESA-3: Updated Survival
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
